

## 7 Literaturverzeichnis

1. Aktas, O., S. Waiczies, et al. (2001). "Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis." *J Neuroimmunol* 114(1-2): 160-7.
2. Amran, D., H. Renz, et al. (1994). "Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin." *Clin Immunol Immunopathol* 73(2): 180-6.
3. Andersson, U., L. Bjork, et al. (1994). "Pooled human IgG modulates cytokine production in lymphocytes and monocytes." *Immunol Rev* 139: 21-42.
4. Andersson, U. G., L. Bjork, et al. (1993). "Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG." *Immunology* 79(2): 211-6.
5. Ashkenazi, S., T. G. Cleary, et al. (1988). "Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome." *J Pediatr* 113(6): 1008-14.
6. Aukrust, P., S. S. Froland, et al. (1994). "Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo." *Blood* 84(7): 2136-43.
7. Balandina, A., S. Lecart, et al. (2005). "Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis." *Blood* 105(2): 735-41.
8. Barbano, G., M. N. Saleh, et al. (1989). "Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia." *Blood* 73(3): 662-5.
9. Barbas, C. F., 3rd, A. S. Kang, et al. (1991). "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site." *Proc Natl Acad Sci USA* 88(18): 7978-82.
10. Barbas, C. F., 3rd and R. A. Lerner (1991). "Combinatorial immunoglobulin libraries on the surface of phage (Phabs): rapid selection of antigen-specific Fabs." *Methods Companion Methods Enzymol* 2: 119-124.
11. Barbas, C. F. and D. R. Burton (1993). "Monoclonal Antibodies from Combinatorial Libraries." CSH Laboratory course.
12. Bartt, R.E. (2006). "Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy." *Curr Opin Neurol* 19(4): 341-9
13. Basta, M., P. F. Langlois, et al. (1989). "High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance." *Blood* 74(1): 326-33.
14. Bayry, J., S. Lacroix-Desmazes, et al. (2003). "Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin." *Blood* 101(2): 758-65.
15. Berchtold, P., G. L. Dale, et al. (1989). "Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin." *Blood* 74(7): 2414-7.

16. Bierling, P. and B. Godeau (2005). "Intravenous immunoglobulin for autoimmune thrombocytopenic purpura." *Hum Immunol* 66(4): 387-94.
17. Blasczyk, R., U. Westhoff, et al. (1993). "Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations." *Lancet* 341(8848): 789-90.
18. Brannagan, T. H., 3rd (2002). "Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies." *Neurology* 59(12 Suppl 6): S33-40.
19. Brix, T. H., K. Christensen, et al. (1998). "A population-based study of Graves' disease in Danish twins." *Clin Endocrinol (Oxf)* 48(4): 397-400.
20. Brix, T. H., K. O. Kyvik, et al. (2000). "A population-based study of chronic autoimmune hypothyroidism in Danish twins." *J Clin Endocrinol Metab* 85(2): 536-9.
21. Brod, S. A. (2002). "Ingested type I interferon: state of the art as treatment for autoimmunity." *Exp Biol Med (Maywood)* 227(11): 981-8.
22. Bussel, J. B. (2000). "Fc receptor blockade and immune thrombocytopenic purpura." *Semin Hematol* 37(3): 261-6.
23. Chitnis, T. and S. J. Khoury (2003). "20. Immunologic neuromuscular disorders." *J Allergy Clin Immunol* 111(2 Suppl): S659-68.
24. Clarkson, S. B., J. B. Bussel, et al. (1986). "Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody." *N Engl J Med* 314(19): 1236-9.
25. Crow, A. R., S. Song, et al. (2003). "IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity." *Blood* 102(2): 558-60.
26. Dalakas, M. C. (1997). "Intravenous immune globulin therapy for neurologic diseases." *Ann Intern Med* 126(9): 721-30.
27. Dalakas, M. C. (2002). "Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies." *Neurology* 59(12 Suppl 6): S13-21.
28. Dammacco, F., G. Iodice, et al. (1986). "Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro." *Br J Haematol* 62(1): 125-35.
29. Deng, S. J., C. R. MacKenzie, et al. (1994). "Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display." *J Biol Chem* 269(13): 9533-8.
30. Diegel, M. L., B. M. Rankin, et al. (1994). "Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel." *J Biol Chem* 269(15): 11409-16.
31. Dietrich, G. and M. D. Kazatchkine (1990). "Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an

- immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies." *J Clin Invest* 85(3): 620-5.
32. Dooley, M. A. and S. L. Hogan (2003). "Environmental epidemiology and risk factors for autoimmune disease." *Curr Opin Rheumatol* 15(2): 99-103.
33. Duenas, M., M. Ayala, et al. (1995). "A point mutation in a murine immunoglobulin V-region strongly influences the antibody yield in *Escherichia coli*." *Gene* 158(1): 61-6.
34. Ephrem, A., N. Misra, et al. (2005). "Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin." *Clin Exp Med* 5(4): 135-40.
35. Ericson, S. G., K. D. Coleman, et al. (1996). "Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes." *Br J Haematol* 92(3): 718-24.
36. Fiedler, M. and A. Skerra (1999). "Use of thiophilic adsorption chromatography for the one-step purification of a bacterially produced antibody F(ab) fragment without the need for an affinity tag." *Protein Expr Purif* 17(3): 421-7.
37. Fischer, P. (1997). "Molekulare Charakterisierung humaner Autoantikörper durch kombinatorische Phagen Display-Bibliotheken." *Habilitationsschrift*
38. Fischer, P., N. Jendreyko, et al. (1999). "Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia." *Br J Haematol* 105(3): 626-40.
39. Flesch, B. K., G. Aichtert, et al. (1997). "Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III." *Ann Hematol* 74(1): 15-22.
40. Frank, M. M., V. D. Miletic, et al. (2000). "Immunoglobulin in the control of complement action." *Immunol Res* 22(2-3): 137-46.
41. Fujisawa, K., P. Tani, et al. (1993). "Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens." *Blood* 81(5): 1284-9.
42. Gershwin, L. J. (2005). "Antinuclear antibodies in domestic animals." *Ann N Y Acad Sci* 1050: 364-70
43. Hansen, R. J. and J. P. Balthasar (2002). "Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor." *Thromb Haemost* 88(6): 898-9.
44. Hoffmann, M., M. M. Uttenreuther-Fischer, et al. (2000). "IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia." *Clin Exp Immunol* 121(1): 37-46.
45. Holt, D., J. Brown, et al. (2003). "Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura." *Pediatrics* 111(1): 87-90.

46. Hou, M., D. Stockelberg, et al. (1997). "Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies." *Br J Haematol* 98(1): 64-7.
47. Hurez, V., S. V. Kaveri, et al. (1994). "Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg)." *Ther Immunol* 1(5): 269-77.
48. Im, S. H., D. Barchan, et al. (2000). "Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis." *J Neuroimmunol* 111(1-2): 161-8.
49. Imbach, P., S. Barandun, et al. (1981). "High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood." *Helv Paediatr Acta* 36(1): 81-6.
50. Imholz, B., P. Imbach, et al. (1988). "Intravenous immunoglobulin (i.v. IgG) for previously treated acute or for chronic idiopathic thrombocytopenic purpura (ITP) in childhood: a prospective multicenter study." *Blut* 56(2): 63-8.
51. Ito, W., Y. Iba, et al. (1993). "Effects of substitutions of closely related amino acids at the contact surface in an antigen-antibody complex on thermodynamic parameters." *J Biol Chem* 268(22): 16639-47.
52. Janeway, C. A. and P. Travers (1997). "Die Bedeutung des Immunsystems für Gesundheit und Krankheit." In C. A. Janeway and P. Travers (ed.), *Immunologie*: 341-541
53. Jendreyko, N., M. M. Uttenreuther-Fischer, et al. (1998). "Genetic origin of IgG antibodies cloned by phage display and anti-idiotypic panning from three patients with autoimmune thrombocytopenia." *Eur J Immunol* 28(12): 4236-47.
54. Jerne, N.K. (1974). "Towards a network theory of the immune system." *Ann Immunol (Paris)* 125C: 373-89.
55. Jin, F. and J. P. Balthasar (2005). "Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura." *Hum Immunol* 66(4): 403-10.
56. Kazatchkine, M. D., G. Dietrich, et al. (1994). "V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig)." *Immunol Rev* 139: 79-107.
57. Kazatchkine, M. D. and S. V. Kaveri (2001). "Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin." *N Engl J Med* 345(10): 747-55.
58. Knappik, A. and A. Pluckthun (1995). "Engineered turns of a recombinant antibody improve its in vivo folding." *Protein Eng* 8(1): 81-9.
59. Koffman, B. M. and M. C. Dalakas (1997). "Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases." *Muscle Nerve* 20(9): 1102-7.

60. Kohn, B., C. Weingart, et al. (2006). "Primary immune-mediated hemolytic anemia in 19 cats: diagnosis, therapy, and outcome (1998-2004)." *J Vet Intern Med* 20(1): 159-66.
61. Krebber, A., J. Burmester, et al. (1996). "Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p." *Gene* 178(1-2): 71-4.
62. Lacroix-Desmazes, S., L. Mouthon, et al. (1996). "Immunoglobulins and the regulation of autoimmunity through the immune network." *Clin Exp Rheumatol* 14 Suppl 15: 9-15.
63. Lam-Tse, W. K., A. Lernmark, et al. (2002). "Animal models of endocrine/organ-specific autoimmune diseases: do they really help us to understand human autoimmunity?" *Springer Semin Immunopathol* 24(3): 297-321.
64. Lam, L., C. F. Whitsett, et al. (1993). "Immunologically active proteins in intravenous immunoglobulin." *Lancet* 342(8872): 678.
65. Larson, V. L., V. Perman, et al. (1983). "Idiopathic thrombocytopenic purpura in two horses." *J Am Vet Med Assoc* 183(3): 328-30
66. Lazarus, A. H. and A. R. Crow (2003). "Mechanism of action of IVIG and anti-D in ITP." *Transfus Apher Sci* 28(3): 249-55.
67. Leucht, S., M. M. Uttenreuther-Fischer, et al. (2001). "The B cell superantigen-like interaction of intravenous immunoglobulin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy." *Clin Immunol* 99(1): 18-29.
68. Leung, D. Y. (1996). "Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin." *Clin Exp Immunol* 104 Suppl 1: 49-54.
69. Leung, D. Y., J. C. Burns, et al. (1987). "Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin." *J Clin Invest* 79(2): 468-72.
70. Leung, D. Y., C. P. Kelly, et al. (1991). "Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by *Clostridium difficile* toxin." *J Pediatr* 118(4 ( Pt 1)): 633-7.
71. Lewis, D. C. and K. M. Meyers (1996). "Canine idiopathic thrombocytopenic purpura." *J Vet Intern Med* 10(4): 207-18
72. Lindstrom, J. (2002). "Autoimmune diseases involving nicotinic receptors." *J Neurobiol* 53(4): 656-65.
73. Lindstrom, J., X. Peng, et al. (1998). "Molecular and antigenic structure of nicotinic acetylcholine receptors." *Ann N Y Acad Sci* 841: 71-86.
74. Link, H. and B. G. Xiao (2001). "Rat models as tool to develop new immunotherapies." *Immunol Rev* 184: 117-28.
75. Looney, R. J. and J. Huggins (2006). "Use of intravenous immunoglobulin G (IVIG)." *Best Pract Res Clin Haematol* 19(1): 3-25.

76. Lopez, P. H., F.J. Irazoqui, et al. (2000). "Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies." *J Neuroimmunol* 105: 179-83
77. Nowak-Wegrzyn, A. and H. M. Lederman (1999). "Supply, use, and abuse of intravenous immunoglobulin." *Curr Opin Pediatr* 11(6): 533-9.
78. Osei, A., M. M. Uttenreuther-Fischer, et al. (2000). "Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin." *Arthritis Rheum* 43(12): 2722-32.
79. Prasad, N. K., G. Papoff, et al. (1998). "Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway." *J Immunol* 161(7): 3781-90.
80. Putsche, J., R. Engelbrecht, et al. (2005). "Klinische Befunde, Diagnostik und Verlauf bei Hunden mit autoimmunbedingter Thrombozytopenie (1997-2003)." 13. Jahrestagung FG "Innere Medizin und Klinische Labordiagnostik" der DVG. München, 5.2.-6.2.2005
81. Rhoades, C. J., M. A. Williams, et al. (2000). "Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin." *Blood Rev* 14(1): 14-30.
82. Ronda, N., M. Haury, et al. (1994). "Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg)." *Clin Immunol Immunopathol* 70(2): 124-8.
83. Rossi, F., G. Dietrich, et al. (1989). "Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses." *Immunol Rev* 110: 135-49.
84. Rossi, F., D. R. Jayne, et al. (1991). "Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis." *Clin Exp Immunol* 83(2): 298-303.
85. Rossi, F. and M. D. Kazatchkine (1989). "Anti-idiotypes against autoantibodies in pooled normal human polyspecific Ig." *J Immunol* 143(12): 4104-9.
86. Ruiz de Souza, V., M. P. Carreno, et al. (1995). "Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)." *Eur J Immunol* 25: 1267-73
87. Samuelsson, A., T. L. Towers, et al. (2001). "Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor." *Science* 291(5503): 484-6.
88. Sasso, E. H., G. J. Silverman, et al. (1991). "Human IgA and IgG F(ab')<sub>2</sub> that bind to staphylococcal protein A belong to the VHIII subgroup." *J Immunol* 147(6): 1877-83.
89. Schulze, R. A., R. E. Kontermann, et al. (1994). "Thiophilic adsorption chromatography of recombinant single-chain antibody fragments." *Anal Biochem* 220(1): 212-4.

90. Sewell, W. A. and S. Jolles (2002). "Immunomodulatory action of intravenous immunoglobulin." *Immunology* 107(4): 387-93.
91. Silverman, G. J. (1997). "B-cell superantigens." *Immunol Today* 18(8): 379-86.
92. Sultan, Y., M. D. Kazatchkine, et al. (1984). "Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin." *Lancet* 2(8406): 765-8.
93. Takei, S., Y. K. Arora, et al. (1993). "Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens." *J Clin Invest* 91(2): 602-7.
94. Teeling, J. L., T. Jansen-Hendriks, et al. (2001). "Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia." *Blood* 98(4): 1095-9.
95. Tsubakio, T., Y. Kurata, et al. (1983). "Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura." *Clin Exp Immunol* 53(3): 697-702.
96. Uher, F. and H. B. Dickler (1986). "Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function." *J Immunol* 137(10): 3124-9.
97. Ulrich, H. D., P. A. Patten, et al. (1995). "Expression studies of catalytic antibodies." *Proc Natl Acad Sci U S A* 92(25): 11907-11.
98. Uttenreuther-Fischer, M.M., J.A. Kruger, et al. (2006). "Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?" *J Immunol* 176(12): 7775-86
99. van Leeuwen, E. F., J. T. van der Ven, et al. (1982). "Specificity of autoantibodies in autoimmune thrombocytopenia." *Blood* 59(1): 23-6.
100. van Schaik, I. N., I. Lundkvist, et al. (1992). "Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro." *J Clin Immunol* 12(5): 325-34.
101. Vassilev, T., C. Gelin, et al. (1993). "Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)." *Clin Exp Immunol* 92(3): 369-72.
102. Vassilev, T., M. Yamamoto, et al. (1999). "Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice." *Eur J Immunol* 29(8): 2436-42.
103. Venkatish, N., S-H. Im, et al. (2000). "Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide." *Proc Natl Acad Sci USA* 97: 761-766
104. Vossebeld, P. J., C. H. Homburg, et al. (1997). "The anti-Fc gamma RIII mAb 3G8 induces neutrophil activation via a cooperative actin of Fc gamma RIIIb and Fc gamma RIIa." *Int J Biochem Cell Biol* 29(3): 465-73.

## LITERATURVERZEICHNIS

---

105. Woods, V. L., Jr., E. H. Oh, et al. (1984). "Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP." *Blood* 63(2): 368-75.
106. Xu, C., B. Poirier, et al. (1998). "Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases." *Am J Pathol* 153(4): 1257-66.
107. Yu, Z. and V. A. Lennon (1999). "Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases." *N Engl J Med* 340(3): 227-8.